• Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. 

  Jones, RL; Herzog, TJ; Patel, SR; von Mehren, M; Schuetze, SM; Van Tine, BA; Coleman, RL; Knoblauch, R; Triantos, S; Hu, P; Shalaby, W; McGowan, T; Monk, BJ; Demetri, GD (2021-05-07)

  <h4>Background</h4>As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced ...
• Pathogenic ACVR1^R206H activation by Activin A-induced receptor clustering and autophosphorylation. 

  Ramachandran, A; Mehić, M; Wasim, L; Malinova, D; Gori, I; Blaszczyk, BK; Carvalho, DM; Shore, EM; Jones, C; Hyvönen, M; Tolar, P; Hill, CS

  Fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG) are debilitating diseases that share causal mutations in ACVR1, a TGF-β family type I receptor. ACVR1^R206H is a frequent ...
• Deep Learning Enables Individual Xenograft Cell Classification in Histological Images by Analysis of Contextual Features. 

  Juppet, Q; De Martino, F; Marcandalli, E; Weigert, M; Burri, O; Unser, M; Brisken, C; Sage, D

  Patient-Derived Xenografts (PDXs) are the preclinical models which best recapitulate inter- and intra-patient complexity of human breast malignancies, and are also emerging as useful tools to study the normal breast ...
• Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8⁺ T cell infiltrate. 

  Porter, RJ; Murray, GI; Alnabulsi, A; Humphries, MP; James, JA; Salto-Tellez, M; Craig, SG; Wang, JM; Yoshimura, T; McLean, MH (2021-05-14)

  Colorectal cancer (CRC) remains a leading cause of cancer mortality. Here, we define the colonic epithelial expression of cathelicidin (LL-37) in CRC. Cathelicidin exerts pleotropic effects including anti-microbial and ...
• Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. 

  Lozano, R; Lorente, D; Aragon, IM; Romero-Laorden, N; Nombela, P; Mateo, J; Reid, AHM; Cendón, Y; Bianchini, D; Llacer, C; Sandhu, SK; Sharp, A; Rescigno, P; Garcés, T; Pacheco, MI; Flohr, P; Massard, C; López-Casas, PP; Castro, E; de Bono, JS; Olmos, D (2021-05-12)

  Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We ...

View more